A 52 WEEKS RETROSPECTIVE STUDY OF DUPILUMAB TREATMENT FOR MODERATE TO SEVERE ATOPIC DERMATITIS IN KOREA: LONG-TERM EFFICACY AND SAFETY OF DUPILUMAB IN REAL WORLD PRACTICE

被引：0
|
作者：
Ahn, Jiyoung [1 ]
Jang, Dong Hyek [1 ]
Heo, Seok Jae [2 ]
Lee, Dong Heon [1 ]
Jung, Hye Jung [1 ]
Park, Mi Yeon [1 ]
Seo, Seoung Jun [3 ]
机构：
[1] Natl Med Ctr, Dept Dermatol, Seoul, South Korea
[2] Yonsei Univ, Dept Biostat & Comp, Grad Sch, Seoul, South Korea
[3] Chung Ang Univ, Dept Dermatol, Coll Med, Seoul, South Korea
来源：
ACTA DERMATO-VENEREOLOGICA | 2021年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
OL9
引用
收藏
页码：13 / 13
页数：1
相关论文
共 50 条
  • [31] Dupilumab in Patients with Atopic Dermatitis: A Multicentric, Long-Term, Real-World Portuguese Study
    Torres, Tiago
    Cruz, Maria Joao
    Goncalo, Margarida
    Filipe, Paulo
    Duarte, Bruno
    Alves, Joao
    Alvarenga, Jose Miguel
    Rosa, Gilberto
    Flor, Duarte
    Ramos, Jose
    Sousa, Diogo
    Rosca, Aureliu
    Magalhaes, Cesar
    Claro, Cristina
    Rocha, Joana
    Vilarinho, Catarina
    Mota, Fernando
    Mota, Alberto
    Lopes, Maria Joao Paiva
    [J]. DERMATOLOGY AND THERAPY, 2024, 14 (08) : 2209 - 2221
  • [32] Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study
    Zhou, Bingjing
    Peng, Cong
    Li, Liqiao
    Liu, Runqiu
    Zhu, Lei
    Chen, Xiang
    Li, Jie
    [J]. FRONTIERS IN MEDICINE, 2022, 9
  • [33] A 24-weeks real-world experience of dupilumab in adolescents with moderate-to-severe atopic dermatitis
    Napolitano, Maddalena
    Fabbrocini, Gabriella
    Potestio, Luca
    Fontanella, Giuseppina
    Picone, Vincenzo
    Bennardo, Luigi
    Scalvenzi, Massimiliano
    Patruno, Cataldo
    [J]. DERMATOLOGIC THERAPY, 2022, 35 (08)
  • [34] LONG-TERM SAFETY IN ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS TREATED WITH DUPILUMAB UP TO 4 YEARS
    Blauvelt, A.
    Eichenfield, L.
    Sierka, D.
    Chen, Z.
    Khokhar, F.
    Marco, A. Rodriguez
    Shabbir, A.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S19 - S19
  • [35] Dupilumab provides long-term efficacy over 2.5 years in adults with moderate-to-severe atopic dermatitis
    Cork, Michael
    Beck, Lisa
    Bissonnette, Robert
    Wollenberg, Andreas
    Simpson, Eric
    Praestgaard, Amy
    Aamodt, Kimberly
    Rossi, Ana
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 : 69 - 69
  • [36] Long-term drug survival of dupilumab and associated predictors in moderate-to-severe atopic dermatitis: A real-world prospective cohort study
    Pezzolo, Elena
    Rossi, MariaTeresa
    Caroppo, Francesca
    Bianchelli, Tommaso
    Fortina, Anna Belloni
    Giacchetti, Alfredo
    Pinton, Piergiacomo Calzavara
    Naldi, Luigi
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (06) : E757 - E759
  • [37] Long-term dupilumab treatment for 100 weeks reduces serum TARC and total IgE in patients with moderate-to-severe atopic dermatitis
    Beck, L. A.
    Thaci, D.
    Bissonnette, R.
    Deleuran, M.
    Harel, S.
    Chen, Z.
    Shumel, B.
    Rossi, A. B.
    [J]. ALLERGY, 2020, 75 : 27 - 28
  • [38] Efficacy and safety of dupilumab in atopic dermatitis in elderly patients: a retrospective study
    Napolitano, M.
    Fabbrocini, G.
    Scalvenzi, M.
    Blasio, C.
    Stingeni, L.
    Patruno, C.
    [J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2020, 45 (07) : 888 - 890
  • [39] Long-term dupilumab treatment up to 100 weeks reduces serum biomarkers in adult patients with moderate-to-severe atopic dermatitis
    Thaci, D.
    Bissonnette, R.
    Deleuran, M.
    Harel, S.
    Chen, Z.
    Levit, N. A.
    Rossi, A. B.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E122 - E122
  • [40] Long-term dupilumab treatment up to 100 weeks has no impact on serum lipids in patients with moderate-to-severe atopic dermatitis
    Wollenberg, A.
    Bieber, T.
    Khokhar, F. A.
    Chen, Z.
    Shumel, B.
    Rossi, A. B.
    [J]. ALLERGY, 2020, 75 : 192 - 193
12345